Key Points Surrozen reported GAAP EPS of $2.55 for Q2 2025, exceeding expectations by $3.66 per share (GAAP) due to significant one-time and non-cash gains. Surrozen recorded $1.0 million in research ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or ...

A leading scientist, a businesswoman and a disease-free patient come together to tell the full story of the promising ...

Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while ...

Cuts to the NIH hurting the scientific community at large, but cuts to the NIH hurt our families and friends in our home ...

August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.44. Operator: Good morning. My name is John, and I'll be your conference ...

Carmen Keogh, 33, believed she was in perfect health when a routine check-up identified her body was riddled with tumours.

Knowable Magazine reports that studying dogs' cancers offers insights into human cancer, due to similar pathways and faster ...

Two days after being taken to hospital Malcolm was diagnosed with immunotherapy-related myocarditis, a rare but known ...

Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure ...

A man who 'jumped at the opportunity' to take part in a miracle drug trial died with days of starting the treatment, says his ...

On December 9, 2024 Carmen was diagnosed with Stage 4C metastatic melanoma cancer, believed to have originated from that ...